The treatment revolution in psoriasis and psoriatic arthritis (PsA) has been among the most dramatic in recent dermatology and rheumatology history. The introduction of IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), and TNF inhibitors has given clinicians tools capable of achieving clear or almost-clear skin in the majority of patients with moderate-to-severe plaque psoriasis. For psoriatic arthritis, these same drug classes plus JAK inhibitors have transformed outcomes.
But expanded treatment options mean expanded administrative demands. Each biologic therapy requires prior authorization, periodic re-authorization, specialty pharmacy coordination, and clinical monitoring. For the approximately 7.5 million Americans living with psoriasis—and the roughly 30 percent who develop psoriatic arthritis, according to the National Psoriasis Foundation—effective access to these therapies depends on practices that can manage these administrative workflows efficiently.
In 2026, psoriasis and PsA clinics are turning to virtual assistants to handle this administrative infrastructure.
Prior Authorization for IL-17, IL-23, and TNF Inhibitors
Biologic prior authorization for psoriasis and PsA involves demonstrating inadequate response or intolerance to conventional treatments, body surface area or PASI score documentation, and sometimes step-therapy through an older biologic before coverage is granted for a newer agent. The specific requirements vary by payer and change with formulary updates.
A virtual assistant trained in dermatology and rheumatology workflows maintains a payer-specific PA requirement library, prepares complete authorization packages, and submits to payer portals on defined pre-expiration timelines. The VA tracks PA expiration dates across the entire biologic-treated patient panel, ensuring that re-authorization is initiated early enough to prevent treatment gaps.
When step-therapy requirements are clinically inappropriate for a specific patient, the VA prepares step-therapy exception request documentation, working with the treating physician to document the clinical rationale.
Specialty Pharmacy Coordination
Self-injectable biologics for psoriasis and PsA are dispensed exclusively through specialty pharmacies and require active coordination to maintain supply continuity. Insurance changes, formulary substitutions, and prior authorization lapses can interrupt supply mid-treatment course, leading to disease flares and patient frustration.
A VA monitors specialty pharmacy refill status for each patient, flags approaching refill deadlines, coordinates insurance re-verification, and helps patients navigate manufacturer copay assistance programs. Many IL-17 and IL-23 inhibitor manufacturers offer robust patient assistance programs; a VA ensures that eligible patients are enrolled and that enrollment is renewed annually before benefits lapse.
PASI and BSA Documentation for Authorization and Quality Reporting
Accurate psoriasis severity documentation is both a clinical necessity and a prior authorization requirement. PASI (Psoriasis Area and Severity Index) scores and body surface area (BSA) estimates must be recorded at baseline and at defined intervals. A VA supports documentation completeness by reviewing encounter notes against authorization requirements, flagging visits where required severity scores are not documented, and ensuring that monitoring data is available when re-authorization packages are assembled.
Infusion Scheduling for IV Biologics
Some psoriasis and PsA patients receive IV infliximab, a TNF inhibitor administered by infusion. Managing infusion suite scheduling, pre-authorization confirmation, and drug coordination for these patients parallels the infusion coordination workflow in rheumatology practices. A VA maintains the infusion calendar, confirms pre-infusion authorization, and coordinates with the specialty or hospital pharmacy on drug delivery.
Managing Dermatology-Rheumatology Care Coordination
Patients with psoriatic arthritis are often co-managed by a dermatologist and a rheumatologist. The treating teams must share treatment decisions, particularly when systemic therapy choices affect both skin and joint disease. A VA ensures that visit summaries and treatment decisions are communicated between co-managing providers, reducing the risk of conflicting therapeutic plans.
Patient Engagement and Monitoring Compliance
Biologic therapy for psoriasis requires baseline and periodic screening for TB, hepatitis B, and in some cases cardiovascular risk factors. A VA manages the screening calendar, sends reminders for required tests, and follows up on outstanding results before biologic initiation or continuation.
Clinics ready to build scalable biologic program support can explore dedicated VA services at Stealth Agents.
Sources
- National Psoriasis Foundation, "Psoriasis Statistics 2025," psoriasis.org
- American Academy of Dermatology, "Biologic Therapy Guidelines for Psoriasis 2024," aad.org
- American College of Rheumatology, "Psoriatic Arthritis Treatment Guidelines 2024," rheumatology.org